a proven track record across a variety of projects and situations
requiring our experts to come to the table, take part in execution and
build a path forward.The virtual model works!
NEUROQUEST AND CONCEPT 2 CLINIC INC. ANNOUNCES RESULTS
OF EXTENSIVE MARKET RESEARCH
May 24, 2016: NeuroQuest Inc. (http://www.neuroquest.ca), and its joint-venture partner Concept 2
Clinic Inc. (http://www.concept2clinic.com) (together, "Company") today announced that the results
from an extensive market research highlight the need for new treatment options for neuropathic
pain (NP). Details from the study indicated that currently approved drugs have low efficacy
and/or result in severe side effects, especially for orally given drugs, resulting in widespread
unmet needs among a large section of patients.
The topical pain market presents an attractive market entry proposition, primarily due to the
segment market growth and lower competitive barriers. The topical pain market, a segment of
the transdermal drug market, is estimated to grow by 9.7% CAGR, outpacing the global pain
market, which is estimated to grow at a CAGR of 3%.
This research has shown that the Company's lead NP drug candidates, NQ1123 and PN34, in
the topical segment, represents strong candidates to overcome many of the current therapeutic
limitations of neuropathic pain management primarily due to minimal side effects, strong safety
profile, and multi-mechanism mode of action, which not only improves efficacy but could make
NQ1123 and PN34 the only multi-mechanism topical drug products on the market.
"Recent publications (See Reference) suggest that pain is a multi-mechanism phenomenon.
These observations are consistent with the fact that successfully approved drugs for pain is
multi-mechanistic, and there have been numerous failures of pipeline drugs developed with a
single mechanism approach." said Robert Cervelli, NeuroQuest's Chief Executive Officer. "This
market research concluded that, based on historical deals in the topical segment, with our
unique multi-mechanism mode of action, NQ1123 and PN34 could command a larger valuation
and upfront cash between $10M and $100M USD."
"PN-34 natural bioactive has minimal toxicity and is classified as Generally Recognized as Safe,
GRAS, as defined by US-FDA. PN34 as a topical product, do not compete with the crowded
oral market. In fact, pain treatment plan have increasingly suggested the combination of both
topical and oral products, in order to increase their effectiveness" said YC Lee, Ph.D., Concept
2 Clinic's Managing Director. "Our formulations were specifically designed and developed to
provide both fast acting and long lasting pain relieve effect throughout the day. The Company
anticipates initiating a safety/efficacy clinical study within Q3 2016, with natural product
application to Health Canada planned for mid- 2017."
Reference: Minett, et al 2015: Endogenous opioids contribute to insensitivity to pain in humans and mice lacking sodium
channel Na 1.7, Nature Communications 6, Article number: 8967
About Neuroquest Inc. and Concept 2 Clinic Inc.
NeuroQuest Inc. (http://www.neuroquest.ca) and its joint-venture partner, Concept 2 Clinic Inc.
(http://www.concept2clinic.com), are Canadian biotechnology companies located in Toronto and
Halifax focused on developing prescription drugs from enhanced chemical modifications to
natural bioactives for the treatment of neurological diseases. NeuroQuest and Concept 2
Clinic are seeking new approaches to modulation of nerve transmission with clinical applications
particularly for neuropathic pain. The company focuses on a first-in-class small molecule drug
discovery platform that is based on bioactives discovered in plant extracts showing efficacy for
neuropathic pain. The company has a proprietary position in both natural bioactives for the
consumer health market and new chemical entities (NCE's) for out-license to the
For further information, please visit the Company's website at www.neuroquest.ca;